The DOJ is probing disclosures to the FDA about different responses that patients had to the blood-thinning drug Plavix, which is developed by Bristol-Myers Squibb (BMY) and Sanofi (SNY). The investigation is looking at how Plavix is less effective in patients who metabolize the drug poorly. State AGs in Mississippi and West Virginia have sued the companies, saying they should have known about the problem since 2003 and that they didn't disclose it in a timely manner.
Erickson Air-Crane (EAC) looks set to extend a two-day-old rally as shares rise 2.39% premarket. The stock is up 25% since Thursday, when the company reported adjusted Q1 earnings that beat estimates and said revenue hit a record $36.9M for the quarter. EAC also updated its guidance. SA contributor Super-trades thinks the shares are worth $56.57 based on the average EBITDA multiple of what he says is the stock's peer group